Identification of the sulfotransferase iso-enzyme primarily responsible for the bio-activation of topical minoxidil.
Pattern hair loss (i.e., androgenetic alopecia) is a common condition afflicting approximately fifty percent of men and women by the age of fifty. Currently, topical minoxidil is the only US FDA approved drug for the treatment of pattern hair loss in men and women.